Friday 6 November 2026 Export VRTX’s income statement to Excel — free account

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024.

Revenue: +11.9%
EPS: −39.2%
Free cash flow: −52.1%

Quarter to September 2026, against a year earlier

547.43 4.93 +0.91%

Follow VRTX

Alert me

Market cap: $137.5B
P/E: 34.6×
Fwd P/E: 33.2×
Dividend yield: —
F-score: 8/9
Altman Z: 12.06
Beneish M: −2.17
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Vertex Pharmaceuticals Incorporated (VRTX) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a price to free cash flow of 42.9×. Over the past ten years it has ranged from 0.0× (June 2025) to 353× (November 2016); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 24.8× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/VRTX/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Vertex Pharmaceuticals Incorporated price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/VRTX/metrics/price-to-free-cash-flow">Vertex Pharmaceuticals Incorporated (VRTX) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	36.3×	—
FY2024	0.0×	—
FY2023	31.7×	70.05%
FY2022	18.7×	(20.58%)
FY2021	23.5×	14.56%
FY2020	20.5×	(45.48%)
FY2019	37.6×	4.89%
FY2018	35.9×	(29.73%)
FY2017	51.0×	(49.99%)
FY2016	102×	—

Period	Price to free cash flow	Change
Sep 2026	41.4×	24.67%
Jun 2026	33.2×	8.55%
Mar 2026	30.6×	(15.75%)
Dec 2025	36.3×	21.00%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 353×

Ten-year median 28.4×

Current reading's percentile 82

Company	Price to free cash flow
ROIV Roivant Sciences Ltd. compare	n/m
GMAB Genmab A/S Sponsored ADR compare	n/m
MRNA Moderna, Inc. compare	n/m
RVMD Revolution Medicines, Inc. compare	n/m
RPRX Royalty Pharma PLC compare	23.3×
REGN Regeneron Pharmaceuticals, Inc. compare	25.3×
ONC BeOne Medicines Ltd. - Sponsored ADR compare	30.4×
ARGX argenex SE compare	41.0×
VRTX Vertex Pharmaceuticals Incorporated	42.9×
Biotechnology industry median	24.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Vertex Pharmaceuticals Incorporated (VRTX) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on VRTX

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on VRTX

Stockrow Weekly